Portage Biotech (Portage Biotech) EV-to-FCF

: 0.01 (As of Today)

View and export this data going back to . Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Portage Biotech's Enterprise Value is $-0.12 Mil. Portage Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.57 Mil. Therefore, Portage Biotech's EV-to-FCF for today is 0.01.

The historical rank and industry rank for Portage Biotech's EV-to-FCF or its related term are showing as below:

PRTG' s EV-to-FCF Range Over the Past 10 Years
Min: -16.87 Med: 5.35 Max: 35.9
Current: 0.01

During the past 13 years, the highest EV-to-FCF of Portage Biotech was 35.90. The lowest was -16.87. And the median was 5.35.

PRTG's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 4.27 vs PRTG: 0.01

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), Portage Biotech's stock price is $0.2499. Portage Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.340. Therefore, Portage Biotech's PE Ratio for today is At Loss.

Portage Biotech EV-to-FCF Historical Data

The historical data trend for Portage Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portage Biotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-FCF

Get a 7-Day Free Trial

-179.22

-40.26

-89.44

-16.05

-3.58

Portage Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-FCF	Get a 7-Day Free Trial															-7.94	-3.58	-4.05	-3.08	-2.62

Competitive Comparison

For the Biotechnology subindustry, Portage Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Portage Biotech EV-to-FCF Distribution

For the Biotechnology industry and Healthcare sector, Portage Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Portage Biotech's EV-to-FCF falls into.

Portage Biotech EV-to-FCF Calculation

Portage Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	-0.122	/	-11.565
	=	0.01

Portage Biotech's current Enterprise Value is $-0.12 Mil.
Portage Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.57 Mil.

Portage Biotech (NAS:PRTG) EV-to-FCF Explanation

Portage Biotech's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.2499	/	-8.340
	=	At Loss

Portage Biotech's share price for today is $0.2499.
Portage Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.340.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Portage Biotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Portage Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Portage Biotech (Portage Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (NAS:PRTG) » Definitions » EV-to-FCF

Comparable Companies

Traded in Other Exchanges

N/A

Address

Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110

Website

https://www.portagebiotech.com

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.